summary: The authors investigated a method to evaluate a treatment switching approach, namely treatment change after one multiple sclerosis (MS) relapse. They studied patients who experienced a relapse while on a first-line disease-modifying therapy, glatiramer acetate and were divided into two groups: those who changed treatment and those who did not. No difference was observed between the two groups and the authors concluded that a single relapse may not be sufficient to indicate treatment failure. However, other studies should be done to better understand the role of confounding value.

authors: Healy BC, Glanz BI, Stankiewicz J, Buckle G, Weiner H, Chitnis T.

source: Mult Scler. 2010 Aug 24.

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: